---
document_datetime: 2023-09-21 19:26:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/laventair-ellipta-epar-all-authorised-presentations_en.pdf
document_name: laventair-ellipta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8494768
conversion_datetime: 2025-12-30 10:00:16.407663
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength      | Pharmaceutical Form              | Route of Administration   | Immediate Packaging   | Pack size                             |
|------------------|-------------------|---------------|----------------------------------|---------------------------|-----------------------|---------------------------------------|
| EU/1/14/899/001  | Laventair Ellipta | 55 µg / 22 µg | Inhalation powder, pre-dispensed | Inhalation use            | blister (alu)         | 1 inhaler (7 doses)                   |
| EU/1/14/899/002  | Laventair Ellipta | 55 µg / 22 µg | Inhalation powder, pre-dispensed | Inhalation use            | blister (alu)         | 1 inhaler (30 doses)                  |
| EU/1/14/899/003  | Laventair Ellipta | 55 µg / 22 µg | Inhalation powder, pre-dispensed | Inhalation use            | blister (alu)         | 3 inhalers (3 x 30 doses) (multipack) |